Amgen welcomed Natalia Sennikova on September 1st as part of her new journey.
Public source
Publisher name
Public post
19 years is a long time... On August 31st, I left Kuehne+Nagel to start something completely new. Looking back, the first thing that comes to my mind is the people. I wa…
Company
Amgen
#WeareBiotech
- Industry
- Biotechnology Research
- Location
- Thousand Oaks, US
- Company size
- 10,001+ employees
About Amgen
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
See moreLatest activity
Latest activity from Amgen
42 signals
Research & Knowledge
Amgen announced that a global Phase 3 study evaluating its DLL3-targeting therapy as a first-line maintenance treatment for people with extensive-stage small cell lung cancer met its primary endpoint.
Research & Knowledge
Amgen published results from the GENERator team evaluating 12,026 oligonucleotides and finding regulatory elements beyond the natural comparison range.
Research & Knowledge
Amgen published results from the DISCO team screening 90 designed genes across four reactions and reporting up to 98 percent yield in one reaction.
Discover more
Similar signals
Similar public activity from other companies.
People
Genmab
Genmab welcomed Raja Haddadin as a new employee.
People
NewAmsterdam Pharma Corporation
NewAmsterdam Pharma Corporation welcomed Tom Buettner as a new employee.
People
Genentech
Genentech hired Erin H. to start a new position in Holly Springs, North Carolina.
People
Structure Therapeutics
Structure Therapeutics welcomed Tao Chen as a new employee.
People
CytoHub Inc.